A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single/Multiple Day Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 18- Methoxycoronaridine (18-MC HCl) Administered Orally to Normal Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zolunicant (Primary)
Indications Leishmaniasis; Opioid-related disorders; Substance-related disorders
Focus Adverse reactions
Sponsors Mindmed

Most Recent Events

19 May 2022 Results presented in a MindMed media release.
28 Mar 2022 According to a MindMed media release, topline data from this trial is expected in Q2 2022
04 Jan 2022 According to a MindMed media release, results from this study will inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight